Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin - LARVOL DELTA

Secondary results from KINETICS, a real-world study of lanreotide autogel (LAN) in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) according to Ki67 proliferation index (Ki67) (ESMO 2025) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor

Disease Control in Patients With Acromegaly Switching From Injected Somatostatin Receptor Ligands to Once-Daily Oral Paltusotine: Interim Results of the PATHFNDR-1 Open-Label Extension (ENDO 2025) - "PATHFNDR-1 was a randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of switching to paltusotine in patients whose acromegaly was controlled (IGF-I ≤1.0× ULN) with injected depot somatostatin receptor ligands (SRLs; octreotide LAR or lanreotide depot). In conclusion, once-daily oral paltusotine maintained biochemical and symptom control and was well tolerated during long-term treatment in patients with acromegaly who switched from injected SRLs. Support: Crinetics Pharmaceuticals"

Clinical • Acromegaly • Carcinoid Syndrome • Endocrine Disorders • Fatigue • Infectious Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Nephrology • Orthopedics • Pain • IGF1 • SSTR

The Combination Therapy of Pasireotide LAR Plus Pegvisomant and Cabergoline Relieved Acromegaly-Related Headache in a Female Patient with AIP-Mutated Acromegaly: A Case Report. (PubMed, Endocr Metab Immune Disord Drug Targets) - "This case report highlights the potential benefits of pasireotide in the treatment of refractory headaches, particularly when combined with pegvisomant.  ."

Journal • Acromegaly • Endocrine Disorders • Pain • Pituitary Gland Carcinoma • IGF1 • SSTR

GLP-1 Receptor Agonists in MEN1-Associated Glucagonoma: Exploring Glycemic Control and Tumor Stability (ENDO 2025) - "In June 2024, lanreotide 120 mg monthly was initiated, partially suppressing glucagon (65 pg/mL), but HbA1c remained elevated at 9.6%... GLP-1 receptor agonists, combined with somatostatin analogs, may provide a safe and effective strategy for managing glucagonoma-associated diabetes in MEN1. Additional research is needed to assess their long-term safety and efficacy in functional pNETs."

Diabetes • Endocrine Cancer • Metabolic Disorders • Nephrology • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Renal Calculi • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • Type 2 Diabetes Mellitus

Severe Cyclic Cushing Syndrome Due to Ectopic ACTH Secretion by Appendiceal Carcinoid (ENDO 2025) - "Laboratory workup showed hypokalemia (3.2 mmol/L, n = 3.5-5.3), elevated urine free cortisol (UFC) (473 mcg/24hours, n<50), normal ACTH (16 pg/mL, n = 6-50), normal AM Cortisol level (15.3 mcg/dL, n=5-22) and abnormal 1-mg dexamethasone suppression with cortisol 8.8 mcg/dL (n≤1.8)...She was unable to tolerate ketoconazole and was initially treated with lanreotide 120mg every 4 weeks... This case demonstrates the importance of individualized medical management of patients with ectopic ACTH syndrome and highlights the need for consideration of early bilateral adrenalectomy for patients with severe CS and metastatic disease."

Acne Vulgaris • Cushing’s Disease • Endocrine Cancer • Endocrine Disorders • Fatigue • Lung Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Psychiatry • Solid Tumor • Women's Health

Improved Patient‑Reported Outcomes with CAM2029 Treatment, an Octreotide Subcutaneous Depot, in Patients with Acromegaly Previously on Standard-of-Care Injectable Somatostatin Receptor Ligands: Final Analysis of the Core Part of the ACROINNOVA 2 Phase 3 Trial (ENDO 2025) - P3 | "BackgroundStandard-of-care somatostatin receptor ligand therapies (SoC; octreotide long-acting repeatable/lanreotide Autogel) for acromegaly require in-office administration and can be burdensome. CAM2029, a long-acting, octreotide subcutaneous depot developed using FluidCrystal® technology, is conveniently self‑administered via autoinjector pen...Patients/partners were confident about self‑administration and highly satisfied with their experience. CAM2029 has the potential to enhance QoL and treatment satisfaction, both important unmet needs in patients with acromegaly."

Clinical • P3 data • Patient reported outcomes • Acromegaly • Endocrine Disorders • SSTR

CAM2029, an Octreotide Subcutaneous Depot, Provides Long-Term and Sustained Biochemical Control of Acromegaly: Final Analysis of the Core Part of the ACROINNOVA 2 Phase 3 Trial (ENDO 2025) - P3 | "CAM2029, developed using FluidCrystal® technology, is a long-acting octreotide subcutaneous depot designed for convenient self‑administration via an autoinjector pen. In ACROINNOVA 1, a 24-week (W), Phase 3 trial (NCT04076462), CAM2029 achieved superior biochemical control vs placebo (PBO; 72.2% vs 37.5%; P=0.0018) in patients previously controlled on standard of care (SoC; octreotide long-acting repeatable [LAR]/lanreotide Autogel [ATG])...The symptom burden also progressively improved with CAM2029. These results reinforce previous findings, supporting CAM2029 as a new treatment option for acromegaly."

P3 data • Acromegaly • Dermatology • Endocrine Disorders • Infectious Disease • Novel Coronavirus Disease • IGF1

KINETICS: Real-world study of lanreotide autogel (LAN) in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) according to Ki67 proliferation index (Ki67) (ESMO-GI 2025) - "KINETICS included a large cohort of patients with advanced GEP-NETs with Ki67 ≥10%. The study demonstrated real-world effectiveness of LAN as a first-line monotherapy, with a median rwPFS of 17.3 months, and provided further data on GI NETs compared with earlier studies.1 References 1. Merola E. The Oncologist 2021; 26:294−301."

Clinical • Metastases • Real-world • Real-world evidence • Oncology • Pancreatic Cancer • Solid Tumor

RIALTO: Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (clinicaltrials.gov) - P3 | N=166 | Recruiting | Sponsor: Grupo Espanol de Tumores Neuroendocrinos | Not yet recruiting ➔ Recruiting

Enrollment open • Endocrine Cancer • Neuroendocrine Tumor • Solid Tumor

Mixed Neuroendocrine and Non-neuroendocrine Tumor of Pancreato-Biliary Origin Treated Successfully with Peptide Receptor Radionuclide Therapy. (PubMed, J Gastrointest Cancer) - "PRRT is currently not used in treatment protocols for the management of MiNENs; however, it could be considered a treatment option in patients with MiNENs, where there is a predominant component of well-differentiated NETs with 68 Ga-DOTATATE avid lesions."

Journal • Endocrine Cancer • Hepatology • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor

Effects of lanreotide autogel immediately after a single injection for thyrotropin-producing pituitary tumor. (PubMed, Endocrinol Diabetes Metab Case Rep) - "This case demonstrates that significant therapeutic effects can be achieved within days after a single injection of LAN-ATG. This approach could facilitate earlier surgical intervention, potentially improving patient outcomes and optimizing preoperative management strategies."

Journal • Endocrine Cancer • Endocrine Disorders • Neuroendocrine Tumor • Oncology • Pituitary Gland Carcinoma • Solid Tumor

A phase 2 study of lanreotide as a therapy for pheochromocytomas (PCs) and paragangliomas (PGs). (ASCO 2025) - P2 | " Conducted clinical trial to assess efficacy/toxicity of Somatuline Depot / Lanreotide Autogel every 4 weeks in patients with advanced/metastatic PC/PG. These data demonstrate efficacy for lanreotide in the treatment of PC/PG comparable to that previously found in NETs with prolonged disease stability the primary outcome. Given emerging data with PC and PG reports limited efficacy for Lutathera with meaningful toxicity, these data with lanreotide achieving a longer median PFS support a management strategy for PC/PG similar to that employed with NETs. Begin with a SSTR antagonist, extract its benefit and delay Lutathera administration until meaningful, consistent disease progression is documented."

P2 data • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR

First-line somatostatin analog therapy in small intestinal and pancreatic neuroendocrine tumors: real-world data from a single center (OeGHO-AHOP 2025) - "Lanreotide autogel was administered in 66% of patients (81% of pan-NET) and octreotide LAR in 34% (42% of si-NET). The median OS from treatment start was 93.5 months. Conclusion : These data highlight the long periods of disease stabilization that can be seen with SSA in enteropancreatic NET."

Clinical • Real-world • Real-world evidence • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor • SSTR

Advanced Malignant insulinoma : When everything else fails , treatment with 177Lu-DOTATATE comes to the rescue (ESPE-ESE 2025) - "7 months prior to the referral, he had been diagnosed with a grade G1, stage IV pancreatic (PNET) gastrinoma and started on PPIs,lanreotide 120mg every 28 days and everolimus achieving stabilization of the pancreatic and hepatic lesions after 6 months of treatment .We suspected a switch in functioning syndrome so we proceeded to initiate treatment with diazoxide after we confirmed hyperinsulinemic hypoglycaemia.Despite everolimus diazoxide , lanreotide 120mg/28 days ,Dexamethasone , continuous enteral nutrition and parenteral infusion of glucose iv drip therapy, the episodes did not subsided. Eleven months after the first dose of 177Lu- DOTATATE the patient continued without hypoglycemia and with normal serum proinsulin and insulin concentrations .A somatostain receptors scan with TC 99 after the fourth dose showed radiological stability of the lesions.The patient regained the sense of well-being and transitioned to working full-time. In our experience, the use of..."

Metastases • Endocrine Cancer • Endocrine Disorders • Hepatology • Hypoglycemia • Neuroendocrine Tumor • Pancreatic Cancer • Solid Tumor

A REAL-WORLD STUDY OF LANREOTIDE AUTOGEL FOR THE TREATMENT OF PATIENTS WITH ACROMEGALY IN CHINA: BASELINE INTERIM ANALYSIS (ESPE-ESE 2025) - "66.7% of the patients had undergone pituitary transsphenoidal surgery, 31.0% had radiotherapy, and 41.9% had prior medications (Octreotide LAR, 27.1%; Bromocriptine, 10.1%; and Cabergoline, 3.9%). CONCLUSIONS This interim analysis shows the study mainly included postoperative patients with pituitary macroadenomas and multiple comorbidities. LAN was administered at doses of 90 mg and 120 mg half each, predominately once every 28 days in Chinese patients with acromegaly."

Clinical • Real-world • Real-world evidence • Acromegaly • Cardiovascular • Endocrine Cancer • Endocrine Disorders • Fatigue • Heart Failure • Hypertension • Musculoskeletal Diseases • Musculoskeletal Pain • Obstructive Sleep Apnea • Oncology • Orthopedics • Pain • Pituitary Gland Carcinoma • Respiratory Diseases • Sleep Apnea • Sleep Disorder • IGF1

CAM2029, a self-administered subcutaneous octreotide depot, improved PROs and symptoms in patients with acromegaly in the ACROINNOVA 2 Phase 3 trial: final analysis of the core phase results (ESPE-ESE 2025) - P3 | "CAM2029 utilises FluidCrystal® technology and provides a long-acting octreotide subcutaneous depot, self‑administered via an autoinjector pen. ACROINNOVA 1 (NCT04076462) was a Phase 3, 24-week, randomised, double-blind trial of CAM2029 in patients who are biochemically controlled (insulin-like growth factor-I [IGF-I] ≤ upper limit of normal [ULN] on standard-of-care [SoC] somatostatin receptor ligands at baseline [octreotide long-acting repeatable/lanreotide Autogel])...ACROINNOVA 2 demonstrates the combined patient benefits of convenient administration, improved QoL, treatment satisfaction and symptom control provided by CAM2029. Table: PROs/symptom burden AcroQoL and TSQM (Higher scores indicate improvement) AcroQoL (range 0–100) Total score TSQM domain scores (range 0–100) Convenience Effectiveness Global satisfaction AIS (Lower scores indicate improvement) AIS Overall score (range 0–18) CI, confidence interval."

Clinical • P3 data • Acromegaly • Endocrine Disorders • IGF1 • SSTR

A rare coexistence of Acromegaly with metastatic Adrenocortical carcinoma. (ESPE-ESE 2025) - "Hence, he was commenced on lanreotide 120 mg monthly injections...Therefore pegvisomant, lanreotide and hydrocortisone were discontinued...He was initiated on Mitotane and Metyrapone with hydrocortisone...He was initiated on enoxaparin for IVC thrombus, unfortunately, the tumour bled resulting in further deterioration and death... Acromegaly is associated with greater morbidity and a high incidence of tumours, possibly due to the permissive role of elevated GH and IGF-I levels. Adrenal lesions seem more frequent in acromegaly than in the general population, however, no single factor (GH/IGF-I levels or disease duration) predicts them. Certain genetically inherited conditions are associated with aggressive pituitary tumours and ACC."

Metastases • Acromegaly • Adrenal Cortex Carcinoma • Endocrine Disorders • Genito-urinary Cancer • Oncology • Palliative care • Pituitary Gland Carcinoma • Respiratory Diseases • Solid Tumor • Thrombosis • CDC73 • CDKN1B • IGF1 • PRKAR1A

Multidisciplinary Approach in the Management of Cardiac Metastasis from Small Intestinal Neuroendocrine Tumour: A Case Report (ESPE-ESE 2025) - "Lanreotide 120 mg was initiated with improvement of abdominal symptoms and CgA... CMs from NETs are rare and typically found in advanced disease. In this case, the heart was the first site of distant metastasis. Multidisciplinary discussion enabled clinical diagnosis and appropriate therapy."

Case report • Clinical • Cardiovascular • Endocrine Cancer • Heart Failure • Hematological Malignancies • Lymphoma • Neuroendocrine Tumor • Oncology • Solid Tumor

Calcium as a Tumour Marker in PTHrP-Secreting Pancreatic Neuroendocrine Tumour: A Case of Multimodal Management. (ESPE-ESE 2025) - "Initial treatment with somatostatin analogue (SSA) Sandostatin® LAR® led to excellent response and subsequent normocalcaemia...Progression then led to treatment combination with Peptide Receptor Radionuclide Therapy (PRRT) with Lutathera®...Subsequent hypercalcaemia was poorly controlled with zoledronate and denosumab, leading to the rapid development of bilateral hip osteoarthrosis, requiring joint replacements. As the disease and hypercalcaemia progressed despite a re-trial of Somatuline® Autogel®, chemotherapy was initiated. The patient received 2 cycles of Capecitabine/Temozolomide by 8 years after her original presentation, resulting in a reduction of the primary tumour and liver metastases, along with normocalcaemia. Severe depression ensued, which was managed with citalopram and required a treatment break... PTHrP-secreting PNETs are extremely rare and are associated with hypercalcaemia and increased mortality. Successful management often..."

Clinical • CNS Disorders • Cough • Depression • Endocrine Cancer • Endocrine Disorders • Hepatology • Insomnia • Metabolic Disorders • Neuroendocrine Tumor • Oncology • Orthopedics • Osteoarthritis • Pancreatic Cancer • Psychiatry • Respiratory Diseases • Sleep Disorder • Solid Tumor

Results from the core phase of the open-label, Phase 3 ACROINNOVA 2 trial: CAM2029, a subcutaneous octreotide depot, achieves sustained, long-term biochemical control in acromegaly (ESPE-ESE 2025) - P3 | "In ACROINNOVA 1, a 24-week, Phase 3 trial (NCT04076462), CAM2029 demonstrated superior biochemical control versus placebo (72.2% vs 37.5%; P=0.0018) in patients previously controlled (IGF-I ≤ upper limit of normal [ULN]) on standard-of-care somatostatin receptor ligands (SoC; octreotide long-acting repeatable/lanreotide Autogel). These long-term findings support CAM2029 as an effective new treatment for acromegaly with a safety profile consistent with SoC. Table: Proportion of patients with biochemical control Prior-placebo Prior‑CAM2029 Directly-enrolled Endpoint(s) Timepoint n/Nall* (%) IGF-I ≤ULN SoC baseline 17/18 (94.4) 33/36 (91.7) 12/81 (14.8) Placebo baseline† 5/18 (27.8) – – W50/52 mean 17/18 (94.4) 31/35 (88.6) 27/74 (36.5) IGF-I ≤ULN and GH SoC baseline 17/18 (94.4) 33/36 (91.7) 12/81 (14.8) <2.5 µg/L Placebo baseline† 5/18 (27.8) – – IGF-I: W50/52 mean 16/17 (94.1) 29/33 (87.9) 23/74 (31.1) GH: W52 mean *Patients with available data at timepoint;..."

Clinical • P3 data • Acromegaly • Dermatology • Endocrine Disorders • IGF1 • SSTR

Heterozygous Men1(+/T) Knockout Mice Do Not Develop Bronchopulmonary Neuroendocrine Hyperplasia or Neoplasia but Bronchial Adenocarcinoma. (PubMed, Adv Respir Med) - "Heterozygous Men1(+/T) knockout mice do not develop bronchopulmonary NEN or precursor lesions, but pulmonary adenocarcinoma. This surprising result needs to be investigated in more detail."

Journal • Preclinical • Endocrine Cancer • Lung Adenocarcinoma • Lung Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • SYP

Subcutaneous Lanreotide Depot: A Diagnostic Pitfall in Neuroendocrine Tumor Imaging. (PubMed, Cureus) - "A retrospective review of a CT scan taken two months after treatment initiation revealed that these nodules were already present and had gradually increased in number, allowing for their correct identification as persistent lanreotide depots. This case underscores the need for heightened diagnostic awareness to prevent unnecessary interventions and ensure accurate management."

Journal • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor

RIALTO: Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (clinicaltrials.gov) - P3 | N=166 | Not yet recruiting | Sponsor: Grupo Espanol de Tumores Neuroendocrinos

New P3 trial • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor

LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) (clinicaltrials.gov) - P2 | N=10 | Active, not recruiting | Sponsor: Antonio Fojo | Recruiting ➔ Active, not recruiting | N=40 ➔ 10 | Trial completion date: Dec 2023 ➔ Mar 2026 | Trial primary completion date: Dec 2023 ➔ Mar 2026

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • CNS Tumor • Endocrine Cancer • Oncology • Solid Tumor • SSTR

Pharmac funds medicines for liver, ovarian, and neuroendocrine cancers (PHARMAC) - "People with liver, ovarian, and neuroendocrine cancers will have access to more medicines from 1 March 2025. Pharmac will fund: atezolizumab and bevacizumab for liver cancer that can’t be removed by surgery; bevacizumab for advanced ovarian cancer; lanreotide for neuroendocrine cancers, bowel blockages caused by cancer, and for a growth disorder called acromegaly....Ngawati says that funding atezolizumab and bevacizumab is a significant milestone for some people with liver cancer in New Zealand."

Reimbursement • Hepatocellular Cancer • Neuroendocrine Carcinoma • Ovarian Cancer